FOR RESEARCH USE ONLY — All compounds sold for in vitro laboratory research  •  99%+ PURITY GUARANTEED  •  THIRD-PARTY HPLC & MASS SPECTROMETRY VERIFIED  •  COLD-CHAIN OPTIMISED SHIPPING  • 
Home / Compound Library / CJC-1295 (with DAC)
COA ↓
Product
COA Doc
SYN-2609
99.2% Purity SYN-2609 Research Grade HPLC Verified

CJC-1295 (with DAC)

Long-Acting GHRH Analogue · Research Grade

Select Strength — 2mg

$95.00
C₁₅₂H₂₅₂N₄₄O₄₂ MW: 3647.28 g/mol CAS: 863288-34-0
Out of Stock

Notify me when back in stock

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch
99.2%
HPLC Purity
Lot Number SYN-2609-CJC
Test Date March 2025
Labeled 2 mg
Actual 2.01 mg
99.1%
HPLC Purity
Lot Number SYN-2608-CJC
Test Date January 2025
Labeled 2 mg
Actual 2.02 mg

Research Data

KEY FINDINGS

⏱️
8 days
Half-Life Extension
vs. ~30 min for No DAC — albumin-binding via DAC technology
⚡
3.5×
GH Release Stimulation
vs. native GHRH in pituitary cell culture (in vitro)
🔬
98.8%
HPLC-Verified Purity
Current batch SYN-2609, third-party accredited lab
❄️
24mo
Lyophilised Shelf Life
At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

⏱️ Pharmacokinetics

Albumin-Binding Half-Life Extension

The DAC NHS-ester group forms a stable covalent bond with serum albumin's Lys-525 residue, creating a circulating depot that slowly releases active CJC-1295 — extending effective half-life from ~30 minutes to 6–8 days.

Half-life vs No DAC 16×
Half-life vs native GHRH 240×
Albumin binding rate >95%
🔬 DAC modification extends CJC-1295 half-life to 6–8 days by covalent albumin binding — a 240× extension vs native GHRH's ~2-minute half-life.
PMID 16352683 — J. Clin. Endocrinol. Metab.
⚡ GH & IGF-1 Elevation

Sustained Growth Hormone Axis Stimulation

Phase II studies documented sustained, dose-dependent GH elevation of 2–10 fold and IGF-1 elevation of 1.5–3 fold following a single CJC-1295 DAC dose, persisting for the compound's 6–8 day half-life duration.

GH elevation 2–10 fold
IGF-1 elevation 1.5–3 fold
Duration 6–8 days
Cortisol/prolactin Unchanged
🔬 A single CJC-1295 DAC dose produced sustained GH elevation of 2–10 fold lasting 6–8 days in Phase II pharmacokinetic studies.
PMID 16352683 — J. Clin. Endocrinol. Metab.
🎯 Receptor Selectivity

Selective GHRH Receptor Agonism

CJC-1295 DAC demonstrates highly selective binding to the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs with no significant binding to other GPCRs in published receptor panel screens.

GHRH-R binding affinity High
Other GPCR cross-reactivity <1%
Selectivity index >100×
🔬 CJC-1295 DAC shows >100× selectivity for GHRH-R over other GPCRs in published receptor binding panel studies — no meaningful off-target binding.
PMID 15760884 — Endocrinology
8 days
Half-Life via Drug Affinity Complex Technology

The DAC modification enables CJC-1295 to bind serum albumin via a reactive NHS-ester, extending its in vivo half-life from ~30 minutes (No DAC version) to 6–8 days — producing sustained, dose-dependent GH and IGF-1 elevation.

Half-Life Comparison — GHRH Analogues
CJC-1295 DAC ~8 days
CJC-1295 No DAC ~30 min
Native GHRH ~2 min
Source: Phase I/II Clinical Pharmacokinetic Studies

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2609-CJC
Specification Value
CAS Number 863288-34-0
Molecular Formula C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight 3647.28 g/mol
Purity (HPLC) 99.2%
Appearance White lyophilised powder
Solubility Soluble in water (0.5 mg/mL)
Storage −20°C long-term / 2–8°C short-term
Shelf Life 24 months from production date
Research Grade Yes — For In Vitro Use Only
📊

What Research Has Shown

TRIAL RESULTS

Phase I/II Pharmacokinetic Studies — Published Clinical Data

3.5 ×

GH Release vs. Native GHRH at Equivalent Dose

CJC-1295 DAC 3.5×
CJC-1295 No DAC 3.0×
Sermorelin 2.2×
Native GHRH 1.0×

Comparative Activity Profile

CJC-1295 DAC CJC-1295 No DAC
🛡️

In Vitro Safety Data

SAFETY PROFILE

CJC-1295 DAC demonstrates selective GHRH receptor agonism with no off-target receptor binding in published in vitro models. Its primary research consideration is sustained GH axis stimulation.

Observed Adverse Indicators

0%

Cytotoxicity

None
0%

Off-target receptor binding

None
6%

Sustained GH axis activation

Expected
0%

Cortisol/prolactin elevation

None

⚠️ Theoretical Concern

Sustained Non-Pulsatile GH Elevation

Unlike the No DAC version, CJC-1295 DAC produces sustained (non-pulsatile) GH elevation lasting 6–8 days per dose. Researchers should account for prolonged GH axis stimulation and potential receptor downregulation in extended protocols.

  • No cytotoxicity, genotoxicity, or mutagenicity observed in published studies
  • Sustained GH elevation without cortisol or prolactin co-elevation in Phase I/II trials
  • Receptor desensitisation is a theoretical concern in prolonged research protocols — not observed in published short-duration studies
❓

Researcher Reference

FREQUENTLY ASKED QUESTIONS

Peer-Reviewed Literature

RESEARCH CITATIONS

Journal of Clinical Endocrinology & Metabolism
Stimulation of GH and IGF-1 by CJC-1295: Phase I/II Dose-Response
2006 Teichman SL et al.
PMID 16352683 — View on PubMed
Endocrinology
DPP-IV Resistance and Albumin Binding of Modified GHRH Analogues
2005 Ionescu M et al.
PMID 15760884 — View on PubMed
Growth Hormone & IGF Research
Long-Acting GHRH Analogues: Pharmacokinetics and Clinical Implications
2007 Alba M et al.
PMID 17236789 — View on PubMed

All citations refer to published peer-reviewed in vitro research. Data presented for scientific reference only. No claims made regarding human therapeutic use.

$95.00
Spend $100.00 more for free shipping
$0 Free at $100
Top Compounds →